ArticleFrontiers in pharmacology2025
Xiaoyao Pill alleviates ulcerative colitis by inhibiting ferroptosis of enterocytes via activating Nrf2/Gpx4 signaling pathway.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The treatment of ulcerative colitis (UC) remains a huge challenge worldwide. Xiaoyao Pill (XYP) is a classic TCM formula, which possesses several benefits, including soothing the liver and invigorating the spleen. However, its protective effect on UC and its underlying mechanisms are unknown. Purpose: Here we explored the protective effect and underlying mechanism of XYP against dextran sulfate sodium (DSS)-induced colitis in mice. Methods: The experimental colitis was established by adding 3% DSS on drinking water of mice and the effects of XYP (0.32 and 0.64 mg/kg/d, i.g., by 10 days) in colon tissues was analyzed. Transcriptomic analysis elucidated therapeutic targets, subsequently validated through molecular techniques and cellular assays. NCM460 cell was induced by RSL3 to detect the effect of XYP on ferroptosis and the underlying mechanism. Pathological damage was determined by H&E. Indicators related to intestinal permeability were detected by immunohistochemistry and immunofluorescence. Cytokines levels (TNF-α、IL-1β and IL-6), antioxidant enzymes activities (MDA, SOD and GSH) from colon tissues of each group mice, the level of Fe Results: The results indicated that XYP significantly attenuated DSS-induced colon pathological damage, intestinal barrier, cytokines levels, and increased the antioxidant enzymes activities. Transcriptomic analyses illustrated that XYP might alleviate UC by inhibiting ferroptosis. Moreover, XYP attenuated ferroptosis in DSS-induced colon injury and regulated Nrf2/Gpx4 signaling pathway in DSS-induced mice. Mechanistic experiments verified that XYP activated Nrf2 Conclusion: Taken together, this study evaluates that XYP alleviates DSS-induced colitis mice by inhibiting ferroptosis of enterocytes and its protective effects are associated with activating the Nrf2/Gpx4 signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.